Melanoma drug a winner in lung cancer

An immunotherapy that is PBS-listed for melanoma is also effective in a subset of non-small cell lung cancer (NSCLC) patients, an open-label phase 3 trial shows.

The KEYNOTE-024 trial randomised 305 patients with stage four lung cancer to either pembrolizumab (Keytruda) or platinum-based chemotherapy.

Patients in the study had PD-L1 expression in at least 50% of their tumour cells and were not previously treated with other regimens